Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients

We investigated the effect of single-nucleotide polymorphisms (SNPs) spanning 10 methotrexate (MTX) pathway genes, namely AMPD1, ATIC, DHFR, FPGS, GGH, ITPA, MTHFD1, SHMT1, SLC19A1 (RFC) and TYMS on the outcome of MTX treatment in a UK rheumatoid arthritis (RA) patient cohort. Tagging SNPs were selected and genotyping was performed in 309 patients with predefined outcomes to MTX treatment. Of the 129 SNPs tested, 11 associations were detected with efficacy (P-trend ⩽0.05) including four SNPs in the ATIC gene (rs12995526, rs3821353, rs7563206 and rs16853834), six SNPs in the SLC19A1 gene region (rs11702425, rs2838956, rs7499, rs2274808, rs9977268 and rs7279445) and a single SNP within the GGH gene (rs12681874). Five SNPs were significantly associated with adverse events; three in the DHFR gene (rs12517451, rs10072026, and rs1643657) and two of borderline significance in the FPGS gene. The results suggest that genetic variations in several key MTX pathway genes may influence response to MTX in the RA patients. Further studies will be required to validate these findings and if confirmed these results could contribute towards a better understanding of and ability to predict MTX response in RA.

[1]  B. Bresnihan,et al.  QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries , 2007, Annals of the rheumatic diseases.

[2]  M. Liang,et al.  Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. , 2006, Arthritis and rheumatism.

[3]  J. Kremer,et al.  Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study , 2005, Annals of the rheumatic diseases.

[4]  J. Kremer,et al.  Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[5]  J. Kremer,et al.  Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. , 2004, Pharmacogenetics.

[6]  Katie Smith,et al.  Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[7]  M. Kennedy,et al.  Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate , 2010, Pharmacogenetics and genomics.

[8]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[9]  S. Shankar,et al.  Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians , 2009, Pharmacogenetics and genomics.

[10]  T Pullar,et al.  BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. , 2008, Rheumatology.

[11]  S. Mori,et al.  Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. , 2012, Drug metabolism and pharmacokinetics.

[12]  D. Tokunaga,et al.  ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. , 2006, Clinical and experimental rheumatology.

[13]  F Guillemin,et al.  Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology , 2005, Annals of the rheumatic diseases.

[14]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[15]  M. Weinblatt,et al.  Efficacy of low-dose methotrexate in rheumatoid arthritis. , 1985, The New England journal of medicine.

[16]  R. Straub,et al.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[17]  Judith A M Wessels,et al.  Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. , 2006, Arthritis and rheumatism.

[18]  C. Allaart,et al.  A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[19]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[20]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[21]  M. A. van de Laar,et al.  Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[22]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[23]  B. Cronstein.  Going with the flow: methotrexate, adenosine, and blood flow , 2006, Annals of the rheumatic diseases.

[24]  F. Wolfe,et al.  Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. , 2002, Rheumatology.

[25]  I. Bruce,et al.  Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX , 2008, Rheumatology.

[26]  G. Jones,et al.  The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. , 2003, Rheumatology.

[27]  J. Kremer,et al.  Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[28]  A. Chopra,et al.  Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients? , 2008, Clinical Rheumatology.

[29]  B. Dijkmans,et al.  Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. , 2001, Arthritis and rheumatism.

[30]  M. Guttadauria,et al.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. , 1985, Arthritis and rheumatism.

[31]  G. Alarcón,et al.  Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. , 1989, Arthritis and rheumatism.

[32]  M. Krajinovic,et al.  Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. , 2002, Blood.

[33]  T Daimon,et al.  Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis , 2009, Journal of clinical pharmacy and therapeutics.

[34]  A. Silman,et al.  Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? , 2008, Annals of the rheumatic diseases.

[35]  P. van Riel,et al.  Methotrexate modulates the kinetics of adenosine in humans in vivo , 2005, Annals of the rheumatic diseases.

[36]  J. D. de Vries-Bouwstra,et al.  Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[37]  N. Kohno,et al.  Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. , 2003, International journal of molecular medicine.

[38]  J. J. Johnson,et al.  Toxicity of methotrexate in rheumatoid arthritis. , 1987, The Journal of rheumatology.

[39]  Y. Goekoop-Ruiterman,et al.  Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. , 2007, Pharmacogenomics.

[40]  Jerzy Swierkot,et al.  Methotrexate in rheumatoid arthritis. , 2006, Pharmacological reports : PR.

[41]  S. Shankar,et al.  Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians , 2008, Pharmacogenetics and genomics.

[42]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[43]  G. Peters,et al.  A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance* , 1998, The Journal of Biological Chemistry.

[44]  Vita Dolžan,et al.  Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism , 2008, European Journal of Clinical Pharmacology.

[45]  Jing Cui,et al.  Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. , 2009, Rheumatology.

[46]  M. Spitz,et al.  Thymidylate Synthase 5′- and 3′-Untranslated Region Polymorphisms Associated with Risk and Progression of Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.

[47]  I. Georgiou,et al.  Transcription regulatory polymorphism −43T>C in the 5′-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy , 2007, Rheumatology International.

[48]  Y-K Wang,et al.  Pharmacogenetic study of 5,10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis , 2008, Annals of the rheumatic diseases.

[49]  J J Anderson,et al.  Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. , 2000, Arthritis and rheumatism.

[50]  K. Ueno,et al.  Methylenetetrahydrofolate reductase and reduced folate carrier-1 genotypes and methotrexate serum concentrations in patients with rheumatoid arthritis. , 2007, The Journal of toxicological sciences.

[51]  M. Droździk,et al.  Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis , 2007, The Pharmacogenomics Journal.

[52]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[53]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[54]  David Gillis,et al.  Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. , 2008, The Journal of rheumatology.

[55]  M. Rieder,et al.  A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. , 2008, Blood.

[56]  A. Hinks,et al.  Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis , 2011, Annals of the rheumatic diseases.

[57]  J. Bertino,et al.  Enzymatic synthesis of polyglutamate derivatives of 7-hydroxymethotrexate. , 1984, Biochemical pharmacology.